{"prompt": "['MCW', 'OUTPATIENT', 'VYXEOS', 'TRIAL', 'worries. [24] We expect the full battery of items to take fewer than 15 minutes to complete, based on our', 'past experience with these measures.', '6 Reporting Requirements', '6.1 Definition of an Adverse Event', 'Any untoward medical occurrence associated with the use of a drug in humans, whether or not considered', 'drug related. (International Conference on Harmonisation [ICH], E2A, E6).', 'This study will utilize the NCI Common Terminology Criteria for Adverse Events (CTCAE) version 5.0,', 'located on the CTEP web site:', 'http://ctep.cancer.gov/protocolDevelopment/electronic applications/ctc.htm', '6.2 Definition of a Serious Adverse Event (SAE)', 'Serious Adverse Event (SAE) means any untoward medical occurrence that results in any of the', 'following outcomes:', 'Death. Results in death.', 'Life threatening. Is life threatening (refers to an AE in which the subject was at risk of death at the', 'time of the event. It does not refer to an event which hypothetically might have caused death if it', 'were more severe).', 'Hospitalization. Requires inpatient hospitalization or prolongation of an existing hospitalization.', 'Disability/incapacity. Results in persistent or significant disability or incapacity. (Disability is', \"defined as a substantial disruption of a person's ability to conduct normal life functions).\", 'Medically important event. This refers to an AE that may not result in death, be immediately life', 'threatening or require hospitalization, but may be considered serious when, based on appropriate', 'medical judgment, may jeopardize the subject, require medical or surgical intervention to prevent', 'one of the outcomes listed above, or involves suspected transmission via a medicinal product of an', 'infectious agent. Examples of such medical events include allergic bronchospasm requiring intensive', 'treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in', 'inpatient hospitalization; any organism, virus or infectious particle (e.g., prion protein transmitting', 'transmissible spongiform encephalopathy), pathogenic or nonpathogenic, is considered an infectious', 'agent.', '6.3 Relationship of an Adverse Event to Study', 'IMPORTANT NOTE:', 'For all collected AEs, the site investigator who examines and evaluates the subject must determine the', \"adverse event's causality, based on temporal relationship and clinical judgment, to BOTH:\", '1. Delivery of drug in an outpatient setting, rather than inpatient setting (e.g., caregiver unavailable,', 'travel issue, etc.)', 'AND ALSO', '2. CPX-351', 'MCW Protocol No: IIT-Michaelis-OutpatientCPX-351', 'p37', 'Version No.: 3', 'Version Date: 04/15/2020']['MCW', 'OUTPATIENT', 'VYXEOS', 'TRIAL', 'The degree of certainty about causality will be graded using the categories below:', 'Definitely Related: There is clear evidence to suggest a causal relationship and other possible', 'contributing factors can be ruled out.', 'Probably Related: There is evidence to suggest a causal relationship and the influence of other', 'factors is unlikely.', 'Possibly Related: There is some evidence to suggest a causal relationship (e.g., the event', 'occurred within a reasonable time after administration of the trial medication). However, the', \"influence of other factors may have contributed to the event (e.g., the subject's clinical condition,\", 'other concomitant events).', 'Unlikely: A clinical event, including an abnormal laboratory test result, whose temporal', 'relationship to CPX-351 administration makes a causal relationship improbable (e.g., the event', 'did not occur within a reasonable time after administration of the trial medication) and in which', \"other drugs or chemicals or underlying disease provides plausible explanations (e.g., the subject's\", 'clinical condition, other concomitant treatments).', 'Unrelated: The AE is completely independent of CPX-351 administration, and/or evidence exists', 'that the event is definitely related to another etiology.', '6.4 Expectedness of an Adverse Event', 'The sponsor is responsible for determining whether an event meets the definition of \"unexpected,\" based', 'on whether the event is listed in the investigator brochure; or if an investigator brochure is not required or', 'available, is not consistent with the risk information described elsewhere in the general investigational', 'plan or elsewhere in the current application.', 'Each site investigator will decide whether an adverse event (AE) is expected or unexpected, but the', 'sponsor is ultimately responsible for determination of expectedness and may therefore override the site', \"investigator's determination of expectedness.\", '6.5 Routine and Expedited Reporting', 'IMPORTANT NOTE:', 'It is expected that all sites will follow best practices to assess AEs and the subsequent attributions for', \"subjects on study. While all AEs will be 'collected' (i.e., recorded in source material such as an electronic\", 'medical record), not all AEs are \"reported\\' centrally (i.e., entered into OnCore data forms or submitted to', 'regulatory agencies). See table below for reporting requirements. Reporting of all events starts after time', 'of consent (such as SAEs prior to enrollment).', 'MCW Protocol No: IIT-Michaelis-OutpatientCPX-351', 'p38', 'Version No.: 3', 'Version Date: 04/15/2020']\n\n###\n\n", "completion": "END"}